clinical_trials
Atacicpet, Sibeprenlimab Halt Decline in Kidney Function in IgA Nephropathy
Confidence86·multiple reportsImportance88NP-EVT-20261024-36204EB
(MedPage Today) -- DENVER -- Two IgA nephropathy drugs -- atacicept (Trutakna) and sibeprenlimab injection (Voyxact) -- showed they were able to slow kidney function decline in final phase III trial efficacy analyses. Atacicept and sibeprenlimab...
Read the original at the primary source
Atacicpet, Sibeprenlimab Halt Decline in Kidney Function in IgA Nephropathy
10/24/2026, 7:05:29 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —